UBS lowered the firm’s price target on Ibotta (IBTA) to $30 from $55 and keeps a Neutral rating on the shares. The expectation reset to “no-growth” buys time for a transformation, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBTA:
- Ibotta downgraded to Equal Weight from Overweight at Wells Fargo
- Ibotta downgraded to Neutral from Buy at Goldman Sachs
- BofA downgrades Ibotta to Underperform after ‘big miss’
- Ibotta downgraded to Underperform from Neutral at BofA
- Ibotta, Inc. Class A: Buy Rating Maintained Amidst CPID Growth Potential and Stable Revenue Outlook